{"organizations": [], "uuid": "17f36f7058d19d603e2c58b7f81e84a45a4c4e82", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-eli-lilly-interested-in-immuno-onc/brief-eli-lilly-interested-in-immuno-oncology-deals-idUSL1N1S10ND", "country": "US", "domain_rank": 408, "title": "BRIEF-Eli Lilly Interested In Immuno-Oncology Deals", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.036, "site_type": "news", "published": "2018-04-24T22:02:00.000+03:00", "replies_count": 0, "uuid": "17f36f7058d19d603e2c58b7f81e84a45a4c4e82"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-eli-lilly-interested-in-immuno-onc/brief-eli-lilly-interested-in-immuno-oncology-deals-idUSL1N1S10ND", "ord_in_thread": 0, "title": "BRIEF-Eli Lilly Interested In Immuno-Oncology Deals", "locations": [], "entities": {"persons": [{"name": "strate", "sentiment": "negative"}, {"name": "lilly", "sentiment": "negative"}, {"name": "bill berkrot", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eli lilly", "sentiment": "negative"}, {"name": "gic", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Eli Lilly and Co:\n* ELI LILLY AND CO CEO SAYS PLANS TO SHARE FINDINGS OF STRATEGIC REVIEW OF ANIMAL HEALTH BUSINESS IN JULY\n* ELI LILLY SAYS INTERESTED IN BUSINESS DEVELOPMENT INCLUDING DEALS IN IMMUNO-ONCOLOGY AND OTHER CANCER DRUGS Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-04-24T22:02:00.000+03:00", "crawled": "2018-04-25T14:31:04.016+03:00", "highlightTitle": ""}